Trade Exicure, Inc. - XCUR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.94 |
Open* | 0.92 |
1-Year Change* | 384.21% |
Day's Range* | 0.87 - 0.93 |
52 wk Range | 0.63-10.16 |
Average Volume (10 days) | 11.26K |
Average Volume (3 months) | 4.73M |
Market Cap | 4.85M |
P/E Ratio | -100.00K |
Shares Outstanding | 4.96M |
Revenue | 9.17M |
EPS | -9.35 |
Dividend (Yield %) | N/A |
Beta | 1.01 |
Next Earnings Date | Mar 23, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 22, 2023 | 0.93 | 0.01 | 1.09% | 0.92 | 0.94 | 0.87 |
Mar 21, 2023 | 0.94 | 0.01 | 1.08% | 0.93 | 0.96 | 0.93 |
Mar 20, 2023 | 0.94 | -0.01 | -1.05% | 0.95 | 0.97 | 0.94 |
Mar 17, 2023 | 0.98 | -0.05 | -4.85% | 1.03 | 1.03 | 0.96 |
Mar 16, 2023 | 0.95 | -0.07 | -6.86% | 1.02 | 1.02 | 0.95 |
Mar 15, 2023 | 1.02 | -0.01 | -0.97% | 1.03 | 1.03 | 1.00 |
Mar 14, 2023 | 1.04 | 0.03 | 2.97% | 1.01 | 1.06 | 0.99 |
Mar 13, 2023 | 1.04 | 0.01 | 0.97% | 1.03 | 1.04 | 0.99 |
Mar 10, 2023 | 1.03 | -0.08 | -7.21% | 1.11 | 1.11 | 0.99 |
Mar 9, 2023 | 1.12 | -0.04 | -3.45% | 1.16 | 1.16 | 1.10 |
Mar 8, 2023 | 1.09 | -0.04 | -3.54% | 1.13 | 1.13 | 1.08 |
Mar 7, 2023 | 1.12 | -0.01 | -0.88% | 1.13 | 1.15 | 1.12 |
Mar 6, 2023 | 1.14 | 0.00 | 0.00% | 1.14 | 1.15 | 1.12 |
Mar 3, 2023 | 1.13 | 0.06 | 5.61% | 1.07 | 1.14 | 1.07 |
Mar 2, 2023 | 1.09 | 0.00 | 0.00% | 1.09 | 1.13 | 1.07 |
Mar 1, 2023 | 1.11 | 0.02 | 1.83% | 1.09 | 1.11 | 1.07 |
Feb 28, 2023 | 1.13 | -0.04 | -3.42% | 1.17 | 1.20 | 1.08 |
Feb 27, 2023 | 1.20 | 0.00 | 0.00% | 1.20 | 1.22 | 1.18 |
Feb 24, 2023 | 1.12 | -0.04 | -3.45% | 1.16 | 1.16 | 1.10 |
Feb 23, 2023 | 1.14 | -0.02 | -1.72% | 1.16 | 1.21 | 1.14 |
Exicure, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | -0.483 | 16.613 | 1.296 | 0.118 | 9.719 |
Revenue | -0.483 | 16.613 | 1.296 | 0.118 | 9.719 |
Total Operating Expense | 62.066 | 42.049 | 27.913 | 21.937 | 21.154 |
Selling/General/Admin. Expenses, Total | 13.087 | 9.955 | 8.573 | 7.818 | 7.046 |
Research & Development | 48.979 | 32.094 | 19.34 | 14.119 | 14.108 |
Operating Income | -62.549 | -25.436 | -26.617 | -21.819 | -11.435 |
Interest Income (Expense), Net Non-Operating | -1.542 | 0.446 | -0.065 | -0.672 | -0.795 |
Other, Net | -0.011 | 0.322 | 0.379 | 0.078 | 0.191 |
Net Income Before Taxes | -64.102 | -24.668 | -26.303 | -22.413 | -12.039 |
Net Income After Taxes | -64.102 | -24.668 | -26.303 | -22.413 | -12.039 |
Net Income Before Extra. Items | -64.102 | -24.668 | -26.303 | -22.413 | -12.039 |
Net Income | -64.102 | -24.668 | -26.303 | -22.413 | -12.039 |
Income Available to Common Excl. Extra. Items | -64.102 | -24.668 | -26.303 | -22.413 | -12.039 |
Income Available to Common Incl. Extra. Items | -64.102 | -24.668 | -26.303 | -22.413 | -12.039 |
Diluted Net Income | -64.102 | -24.668 | -26.303 | -22.413 | -12.039 |
Diluted Weighted Average Shares | 2.95362 | 2.9065 | 1.9222 | 1.37284 | 1.3099 |
Diluted EPS Excluding Extraordinary Items | -21.7029 | -8.4872 | -13.6838 | -16.3261 | -9.1908 |
Diluted Normalized EPS | -21.7029 | -8.4872 | -13.6838 | -16.3261 | -9.1908 |
Total Extraordinary Items | 0 | 0 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 2.565 | 2.118 | -3.677 | 0.079 | 0.997 |
Revenue | 2.565 | 2.118 | -3.677 | 0.079 | 0.997 |
Total Operating Expense | 10.302 | 15.567 | 19.404 | 13.941 | 13.154 |
Selling/General/Admin. Expenses, Total | 3.162 | 4.15 | 2.947 | 3.098 | 2.892 |
Research & Development | 7.14 | 11.417 | 16.457 | 10.843 | 10.262 |
Operating Income | -7.737 | -13.449 | -23.081 | -13.862 | -12.157 |
Interest Income (Expense), Net Non-Operating | -0.591 | -0.372 | -0.445 | -0.405 | -0.32 |
Other, Net | -0.02 | -0.004 | -0.005 | -0.002 | 0 |
Net Income Before Taxes | -8.348 | -13.825 | -23.531 | -14.269 | -12.477 |
Net Income After Taxes | -8.348 | -13.825 | -23.531 | -14.269 | -12.477 |
Net Income Before Extra. Items | -8.348 | -13.825 | -23.531 | -14.269 | -12.477 |
Net Income | -8.348 | -13.825 | -23.531 | -14.269 | -12.477 |
Income Available to Common Excl. Extra. Items | -8.348 | -13.825 | -23.531 | -14.269 | -12.477 |
Income Available to Common Incl. Extra. Items | -8.348 | -13.825 | -23.531 | -14.269 | -12.477 |
Diluted Net Income | -8.348 | -13.825 | -23.531 | -14.269 | -12.477 |
Diluted Weighted Average Shares | 4.03093 | 3.01522 | 2.93654 | 2.93449 | 2.92812 |
Diluted EPS Excluding Extraordinary Items | -2.07099 | -4.58507 | -8.01317 | -4.86252 | -4.2611 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -2.07099 | -4.58507 | -8.01317 | -4.86252 | -4.2611 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 43.666 | 86.322 | 112.776 | 27.663 | 27.638 |
Cash and Short Term Investments | 39.141 | 82.08 | 110.786 | 26.268 | 25.764 |
Cash & Equivalents | 34.644 | 33.262 | 48.46 | 26.268 | 25.764 |
Total Receivables, Net | 0 | 0.011 | 0.271 | 0.013 | 0.03 |
Accounts Receivable - Trade, Net | 0 | 0.011 | 0.035 | 0.003 | 0.013 |
Prepaid Expenses | 3.247 | 4.231 | 1.014 | 1.382 | 1.844 |
Total Assets | 64.868 | 100.444 | 115.263 | 28.756 | 28.987 |
Property/Plant/Equipment, Total - Net | 11.877 | 12.729 | 2.455 | 1.061 | 1.317 |
Property/Plant/Equipment, Total - Gross | 14.544 | 14.469 | 3.772 | 2.25 | 2.166 |
Accumulated Depreciation, Total | -2.667 | -1.74 | -1.317 | -1.189 | -0.849 |
Other Long Term Assets, Total | 9.325 | 1.393 | 0.032 | 0.032 | 0.032 |
Total Current Liabilities | 34.067 | 13.734 | 31.087 | 2.043 | 3.356 |
Accounts Payable | 3.413 | 1.866 | 1.814 | 0.5 | 1.049 |
Accrued Expenses | 6.464 | 3.525 | 2.435 | 1.543 | 1.273 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 6.873 | 0 | 4.965 | 0 | |
Other Current Liabilities, Total | 17.317 | 8.343 | 21.873 | 0 | 1.034 |
Total Liabilities | 53.636 | 38.938 | 34.516 | 7.804 | 9.012 |
Total Long Term Debt | 0 | 16.589 | 0 | 4.925 | 4.855 |
Long Term Debt | 0 | 16.589 | 0 | 4.925 | 4.855 |
Other Liabilities, Total | 19.569 | 8.615 | 3.429 | 0.836 | 0.801 |
Total Equity | 11.232 | 61.506 | 80.747 | 20.952 | 19.975 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
Common Stock | 0.011 | 0.009 | 0.009 | 0.004 | 0.004 |
Additional Paid-In Capital | 181.29 | 167.379 | 162.062 | 75.942 | 53.586 |
Retained Earnings (Accumulated Deficit) | -170.067 | -105.965 | -81.297 | -54.994 | -33.615 |
Total Liabilities & Shareholders’ Equity | 64.868 | 100.444 | 115.263 | 28.756 | 28.987 |
Total Common Shares Outstanding | 3.62574 | 2.92142 | 2.86869 | 1.47845 | 1.3099 |
Short Term Investments | 4.497 | 48.818 | 62.326 | ||
Other Current Assets, Total | 1.278 | 0.705 | |||
Other Equity, Total | -0.002 | 0.083 | -0.027 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 29.182 | 43.666 | 64.147 | 60.647 | 73.987 |
Cash and Short Term Investments | 26.384 | 39.141 | 60.838 | 56.059 | 67.436 |
Cash & Equivalents | 23.89 | 34.644 | 51.885 | 42.587 | 34.296 |
Short Term Investments | 2.494 | 4.497 | 8.953 | 13.472 | 33.14 |
Total Receivables, Net | 0 | 0.027 | 0.044 | 0.224 | |
Accounts Receivable - Trade, Net | 0 | 0 | 0 | 0 | |
Prepaid Expenses | 1.669 | 3.247 | 2.173 | 3.642 | 5.02 |
Other Current Assets, Total | 1.129 | 1.278 | 1.109 | 0.902 | 1.307 |
Total Assets | 41.896 | 64.868 | 77.9 | 74.467 | 87.948 |
Property/Plant/Equipment, Total - Net | 11.393 | 11.877 | 12.288 | 12.383 | 12.535 |
Property/Plant/Equipment, Total - Gross | 14.359 | 14.544 | 14.661 | 14.473 | 14.346 |
Accumulated Depreciation, Total | -2.966 | -2.667 | -2.373 | -2.09 | -1.811 |
Other Long Term Assets, Total | 1.321 | 9.325 | 1.465 | 1.437 | 1.426 |
Total Current Liabilities | 21.361 | 34.067 | 21.98 | 12.745 | 12.763 |
Accounts Payable | 1.918 | 3.413 | 2.485 | 2.25 | 2.976 |
Accrued Expenses | 3.227 | 6.464 | 5.48 | 3.228 | 2.441 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 16.216 | 17.317 | 14.015 | 7.267 | 7.346 |
Total Liabilities | 38.66 | 53.636 | 63.917 | 37.827 | 37.907 |
Total Long Term Debt | 0 | 0 | 16.801 | 16.73 | 16.659 |
Long Term Debt | 0 | 16.801 | 16.73 | 16.659 | |
Other Liabilities, Total | 17.299 | 19.569 | 25.136 | 8.352 | 8.485 |
Total Equity | 3.236 | 11.232 | 13.983 | 36.64 | 50.041 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.012 | 0.011 | 0.009 | 0.009 | 0.009 |
Additional Paid-In Capital | 181.644 | 181.29 | 170.217 | 169.337 | 168.442 |
Retained Earnings (Accumulated Deficit) | -178.415 | -170.067 | -156.242 | -132.711 | -118.442 |
Other Equity, Total | -0.005 | -0.002 | -0.001 | 0.005 | 0.032 |
Total Liabilities & Shareholders’ Equity | 41.896 | 64.868 | 77.9 | 74.467 | 87.948 |
Total Common Shares Outstanding | 4.0931 | 3.62574 | 2.93666 | 2.93626 | 2.93283 |
Current Port. of LT Debt/Capital Leases | 0 | 6.873 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -64.102 | -24.668 | -26.303 | -22.413 | -12.039 |
Cash From Operating Activities | -34.819 | -39.27 | 1.317 | -19.487 | -19.789 |
Cash From Operating Activities | 1.123 | 0.766 | 0.392 | 0.358 | 0.232 |
Non-Cash Items | 4.048 | 2.896 | 1.981 | 2.179 | 1.437 |
Changes in Working Capital | 24.112 | -18.264 | 25.247 | 0.389 | -9.419 |
Cash From Investing Activities | 43.085 | 10.142 | -63.432 | -0.094 | -0.926 |
Capital Expenditures | -0.968 | -3.171 | -1.082 | -0.094 | -0.926 |
Cash From Financing Activities | 1.116 | 15.13 | 84.307 | 20.085 | 26.856 |
Financing Cash Flow Items | -1.125 | -0.711 | -6.518 | -1.957 | -3.699 |
Issuance (Retirement) of Stock, Net | 12.241 | 3.34 | 90.825 | 22.042 | 31.556 |
Issuance (Retirement) of Debt, Net | -10 | 12.501 | 0 | -1.001 | |
Net Change in Cash | 9.382 | -13.998 | 22.192 | 0.504 | 6.141 |
Other Investing Cash Flow Items, Total | 44.053 | 13.313 | -62.35 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -8.348 | -64.102 | -50.277 | -26.746 | -12.477 |
Cash From Operating Activities | -12.756 | -34.819 | -21.022 | -25.885 | -14.809 |
Cash From Operating Activities | 0.302 | 1.123 | 0.829 | 0.546 | 0.263 |
Non-Cash Items | 1.006 | 4.048 | 3.04 | 1.578 | 0.693 |
Changes in Working Capital | -5.716 | 24.112 | 25.386 | -1.263 | -3.288 |
Cash From Investing Activities | 1.995 | 43.085 | 38.977 | 34.533 | 15.297 |
Capital Expenditures | -0.006 | -0.968 | -0.623 | -0.564 | -0.225 |
Other Investing Cash Flow Items, Total | 2.001 | 44.053 | 39.6 | 35.097 | 15.522 |
Cash From Financing Activities | -7.993 | 1.116 | 0.668 | 0.677 | 0.546 |
Financing Cash Flow Items | -0.507 | -1.125 | -0.009 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 0.014 | 12.241 | 0.677 | 0.677 | 0.546 |
Issuance (Retirement) of Debt, Net | -7.5 | -10 | 0 | 0 | 0 |
Net Change in Cash | -18.754 | 9.382 | 18.623 | 9.325 | 1.034 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Exicure, Inc. Company profile
About Exicure Inc
Exicure, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its spherical nucleic acid (SNA) technology. The Company develops XCUR-FXN, which is a spherical nucleic acid (SNA) -based therapeutic candidate for the treatment of Friedreich’s ataxia (FA). XCUR-FXN through its SNA technology incorporates more than one active oligonucleotides in a single SNA molecule. The Company’s therapeutic candidate cavrotolimod (AST-008) is a toll-like receptor 9 (TLR9) agonist designed for immuno-oncology applications utilizing its SNA technology. AST-008 is in a Phase I b/II clinical trial in patients with advanced solid tumors. TLR9 agonists binds to and activate TLR9.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Exicure Inc revenues decreased from $16.5M to -$2.6M. Net loss increased from $12M to $50.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expense - Balan increase of 69% to $36.5M (expense), General and administrative expense - Bal increase of 25% to $7.8M (expense).
Industry: | Bio Therapeutic Drugs |
2430 N. Halsted St.
CHICAGO
ILLINOIS 60614
US
Income Statement
- Annual
- Quarterly
News

China Evergrande offers bond and equity swaps in debt restructuring
Adds proposal detail
15:24, 22 March 2023
Mexico inflation rate brings good news, uncertainty remains -Espinosa
Updates with additional information from interview, context
15:19, 22 March 2023
World refined copper market in 103,000 tonne surplus in January –ICSG
March 22 (Reuters) - The world's refined copper market had a 103,000 tonne surplus in January, compared with a 10,000 tonnes surplus the previous month, the International Copper Study Group (ICSG) said in its latest monthly bulletin.
15:10, 22 March 2023
Fitness chains add financial muscle as more Americans hit the gym
By Deborah Mary Sophia
15:07, 22 March 2023
House Republicans subpoena labor authorities in Starbucks union dispute - WSJ
March 22 (Reuters) - A Congressional committee issued a subpoena to the National Labor Relations Board, alleging that employees of the labor body mishandled union elections at Starbucks Corp SBUX.O cafes in ways that favored unionizing workers, the Wall Street Journal reported on Wednesday, citing a letter.
15:06, 22 March 2023
China Evergrande publishes plan to restructure $22.7 bln offshore debt
HONG KONG, March 22 (Reuters) - China Evergrande Group 3333.HK on Wednesday published long-awaited plans to restructure its $22.7 billion of offshore debt.
15:02, 22 March 2023
Crop merchant Louis Dreyfus to step up spending after earnings boost
Writes through with details, quote
14:59, 22 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com